GlycoMimetics, based in Rockville, Maryland, develops glycomimetic drugs to treat diseases influenced by carbohydrate biology, with candidates like Uproleselan for AML and GMI-1687 for subcutaneous use. The company went public in January 2014 and employs 35 people.
(CBIO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, 's actual EPS was -$4.00, beating the estimate of -$5.10 per share, resulting in a 21.57% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
